131110-76-4

Usage

Uses

Used in Organic Synthesis:
Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate is used as a chiral building block in organic synthesis for the preparation of enantioselective compounds. Its unique structure allows for the creation of complex molecules with specific stereochemistry, which is essential for biological activity and selectivity.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate is used as a key intermediate in the development of new drugs. Its chiral center and functional groups enable the synthesis of biologically active molecules with potential therapeutic applications. Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate's versatility in chemical reactions allows for the exploration of novel drug candidates with improved efficacy and selectivity.
Used in Biochemical Process Studies:
Methyl (R)-2-(Benzylamino)-3-hydroxypropanoate is also utilized in the study of biochemical processes, where its chiral properties can provide insights into the mechanisms of enzyme-catalyzed reactions and the binding of molecules to biological targets. Understanding these interactions can lead to the discovery of new drug targets and the optimization of existing therapeutic agents.

InChI:InChI=1/C11H15NO3/c1-15-11(14)10(8-13)12-7-9-5-3-2-4-6-9/h2-6,10,12-13H,7-8H2,1H3/t10-/m1/s1

Upstream product

• 40216-75-9 (R)-3-Hydroxy-2-{[1-phenyl-meth-(E)-ylidene]-amino}-propionic acid methyl ester 
• 5874-57-7 R-(-)-serine methyl ester hydrochloride 
• 100-52-7 benzaldehyde 
• 2104-89-4 D-serine methyl ester 

Downstream Products

• 852946-10-2 methyl (2R)-3-(2,2-dimethyl-1,1-diphenyl-1-silapropoxy)-2-[benzylamino]propanoate 
• 1258937-54-0 4-allyl 1-[(2R)-2-(benzylamino)-3-methoxy-3-oxopropyl] N-(tert-butoxycarbonyl)-L-aspartate 
• 1342198-58-6 allyl [(3R,6S)-4-benzyl-3-(tert-butoxycarbonylaminomethyl)-2,5-dioxopiperazin-6-yl]acetate 
• 1258937-55-1 allyl [(2S,5R)-4-benzyl-5-(hydroxymethyl)-3,6-dioxopiperazin-2-yl]acetate 
• 1204332-58-0 C₁₉H₂₅N₃O₆ 
• 1365059-89-7 N-methyl-N-benzyl-D-serine methyl ester 
• 1311981-47-1 dimethyl Nα-tert-butoxycarbonyl-Nα'-benzyl-τ-L-histidino-D-alaninate 
• 1311981-39-1 methyl 4R,3-benzyl-2,2-dioxo-1,2,3-oxathiazolidine-4-carboxylate 
• 929048-00-0 (7R,9aR)-7-(hydroxymethyl)-8-(phenylmethyl)hexahydropyrazino[2,1-c][1,4]oxazine-6,9-dione 
• 144001-46-7 1-benzyl-2α-(hydroxymethyl)-4α-nitro-3β-pyrrolidineacetic acid ethyl ester 
• 144001-46-7 1-benzyl-2α-(hydroxymethyl)-4β-nitro-3β-pyrrolidineacetic acid ethyl ester 
• 144001-49-0 1-benzyl-2α-<<<(1,1-dimethylethyl)dimethylsilyl>oxy>methyl>-4β-<(1,3-dioxolan-2-yl)methyl>-4α-nitro-3β-pyrrolidineacetic acid ethyl ester 

Relevant academic research and scientific papers

TETRACYCLIC HETEROARYL COMPOUNDS

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

HIV PROTEASE INHIBITORS

The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Nature-inspired total synthesis of (-)-fusarisetin A

A concise, protecting group-free total synthesis of (-)-fusarisetin A (1) was efficiently achieved in nine steps from commercially available (S)-(-)-citronellal. The synthetic approach was inspired by our proposed biosynthesis of 1. Key transformations of our strategy include a facile construction of the decalin moiety that is produced via a stereoselective IMDA reaction and a one-pot TEMPO-induced radical cyclization/aminolysis that forms the C ring of 1. Our route is amenable to analogue synthesis for biological evaluation.

Synthesis of histidinoalanine: A comparison of β-lactone and sulfamidate electrophiles

Previous syntheses of histidinoalanine (HAL) have led to mixtures of regioisomers and/or stereoisomers. For example, opening of N-Cbz-d-serine- β-lactone (6) with Boc-l-His-OMe (5) gave a 2:1 mixture of τ- and π-regioisomers. The sulfamidate 10, derived f

Orthogonally protected glycerols and 2-aminodiols: Useful building blocks in heterocyclic chemistry

The efficient synthesis of orthogonally protected glycerols, 2-aminopropane-1,3-diols and 2-aminobutane-1,4-diols that can constitute useful tools in heterocyclic chemistry, is reported. These interesting tri-functionalized small synthons were easily prepared from serine or aspartic acid. In addition, these substrates can be readily transformed into their iodide derivatives in very good yields. ARKAT USA, Inc.

CRYSTALLINE FORMS OF A PYRIDINE DERIVATIVE

The invention relates to 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form or in a solvate thereof, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Two syntheses of (-)-kainic acid via highly stereoselective zinc-ene cyclizations

Two concise, high-yielding syntheses of enantioenriched (-)-kainic acid are presented. Both routes feature a Pd-catalyzed Zn-ene cyclization that proceeds with complete diastereoselectivity. The key step can be carried out on a multigram scale, and the ov

PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS

There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein: X represents a nitrogen atom; Y represents -C(H2)-, (-C(H2)-)2, -S(O2)- or -C(=O)-; Z represents -C(H2)-, -S(O2)-, -N(Rz)-, or an oxygen or sulphur atom; A represents hydrogen or -CH2OH; Rz represents hydrogen, C1-6 alkyl, C1-6 alkoxy, -COR7 or -SO2R7; R1 represents halogen, C1-6 alkyl, C1-6 alkoxy, =O, haloC1-6 alkyl, haloC1-6 alkoxy, hydroxyl or -CH2OH; m represents an integer from 0 to 3; R2 represents halogen, =O, C1-6alkyl (optionally substituted by one or more hydroxyl groups), -COOR7, -CONR7R8, C1-6 alkoxy, haloC1-6 alkyl, haloC1-6alkoxy or C1-6 alkyloC1-6 alkyl; n represents an integer from 0 to 3; p and q independently represent an integer from 0 to 2; R3 represents an -aryl, -heteroaryl, -heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl or -heterocyclyl-heterocyclyl group, all of which may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, C1-6 alkyl (optionally substituted by one or more hydroxyl groups), C3-8cycloalkyl, C1-6 alkoxy, hydroxyl, haloC1-6alkyl, haloC1-6 alkoxy, cyano, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO2-C1-6 alkyl, -COR7, -CONR7R8, -NR7R8, -NR7COC1-6 alkyl, -NR7SO2-C1-6alkyl, C1-6 alkyl-NR7R8, -OCONR7R8 , -NR7CO2R8 or -SO2NR7R8 groups; R4 and R5 independently represent C1-6 alkyl, or R4 and R5 together with the carbon atom to which they are attached may together form a C3-8cycloalkyl group; R6 represents halogen, C1-6 alkyl, C3-8cycloalkyl, C1-6 alkoxy, haloC1-6 alkyl or haloC1-6 alkoxy; s represents an integer from 0 to 4; R7 and R8 independently represent hydrogen, C1-6 alkyl or C3-8cycloalkyl; or solvates thereof.

Oxazoloisoquinoline derivatives as thrombin receptor antagonists

Heterocyclic-substituted bi or tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in